MiRNA-155 Mediates TAM Resistance by Modulating SOCS6-STAT3 Signalling Pathway in Breast Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2015 Dec 23

PMID 26692956

Citations 47

Authors

Rong Shen

Yu Wang

Cai-Xia Wang

Miao Yin

Hong-Liang Liu

Jian-Peng Chen

Jun-Qing Han

Wei-Bo Wang

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the second leading cause of cancer induced death in women. Tamoxifen is an endocrine therapy which is administered to 70% of all breast cancer patients with estrogen receptor alpha (ERα) expression. Despite the initial response, most patients eventually acquire resistance to the drug. MicroRNAs (miRNAs) are a class of small non-coding RNAs which have the ability to post-transcriptionally regulate gene expression. Although the role of a few miRNAs has been described in tamoxifen resistance, little is known about how concerted actions of miRNAs targeting biological networks contribute to its resistance. In this study, we identified that miR-155 is frequently up-regulated in breast cancer with tamoxifen resistance. Ectopic expression of miR-155 induces cell survival and resistance to TAM, whereas inhibition of miR-155 causes cells to apoptosis and enhances TAM sensitivity. Further, we identified SOCS6 as a new direct target of miR-155. Sustained overexpression of miR-155 resulted in repression of SOCS6 protein and mRNA levels, and knockdown of miR-155 increased SOCS6 expression. Introduction of SOCS6 cDNA lacking the 3'-UTR abrogated miR-155-induced cell survival and chemoresistance. Finally, it was verified that SOCS6 or inhibition of STAT3 could inhibit miR-155 STAT3 activation and cell proliferation. In conclusion, our study reveals a molecular link between miR-155 and SOCS6-STAT3 and presents an evidence that miR-155 is a critical therapeutic target in breast cancer.

Citing Articles

Soy Isoflavone Genistein Enhances Tamoxifen Sensitivity in Breast Cancer via microRNA and Glucose Metabolism Modulation.

Shpigel J, Luciano E, Ukandu B, Sauane M, de la Parra C Int J Mol Sci. 2025; 26(2).

PMID: 39859445 PMC: 11765730. DOI: 10.3390/ijms26020733.

MiR-363-3p induces tamoxifen resistance in breast cancer cells through PTEN modulation.

Liang Y, Shi C, Wang Y, Fan B, Song W, Shen R Sci Rep. 2024; 14(1):32135.

PMID: 39738797 PMC: 11685982. DOI: 10.1038/s41598-024-83938-8.

Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155.

Qian H, Maghsoudloo M, Jabbarzadeh Kaboli P, Babaeizad A, Cui Y, Fu J Int J Med Sci. 2024; 21(14):2781-2798.

PMID: 39512697 PMC: 11539376. DOI: 10.7150/ijms.102123.

Exosomal microRNAs in breast cancer: towards theranostic applications.

Gulati R, Mitra T, Rajiv R, Rajan E, Pierret C, Enninga E Front Mol Biosci. 2024; 11:1330144.

PMID: 38455764 PMC: 10918471. DOI: 10.3389/fmolb.2024.1330144.

Extracellular vesicles as tools and targets in therapy for diseases.

Kumar M, Baba S, Sadida H, Al Marzooqi S, Jerobin J, Altemani F Signal Transduct Target Ther. 2024; 9(1):27.

PMID: 38311623 PMC: 10838959. DOI: 10.1038/s41392-024-01735-1.

References

Wu Q, Luo G, Yang Z, Zhu F, An Y, Shi Y . miR-17-5p promotes proliferation by targeting SOCS6 in gastric cancer cells. FEBS Lett. 2014; 588(12):2055-62. DOI: 10.1016/j.febslet.2014.04.036. View

Calame K . MicroRNA-155 function in B Cells. Immunity. 2007; 27(6):825-7. DOI: 10.1016/j.immuni.2007.11.010. View

Czyzyk-Krzeska M, Zhang X . MiR-155 at the heart of oncogenic pathways. Oncogene. 2013; 33(6):677-8. PMC: 4047641. DOI: 10.1038/onc.2013.26. View

Kong W, He L, Coppola M, Guo J, Esposito N, Coppola D . MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010; 285(23):17869-79. PMC: 2878550. DOI: 10.1074/jbc.M110.101055. View

Tili E, Croce C, Michaille J . miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol. 2009; 28(5):264-84. DOI: 10.1080/08830180903093796. View

Cui Y, Zhang M, Pestell R, Curran E, Welshons W, Fuqua S . Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 2004; 64(24):9199-208. DOI: 10.1158/0008-5472.CAN-04-2126. View

Sandhu S, Volinia S, Costinean S, Galasso M, Neinast R, Santhanam R . miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci U S A. 2012; 109(49):20047-52. PMC: 3523868. DOI: 10.1073/pnas.1213764109. View

Lu Z, Ye Y, Jiao D, Qiao J, Cui S, Liu Z . miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol Lett. 2012; 4(5):1027-1032. PMC: 3499613. DOI: 10.3892/ol.2012.841. View

Donnem T, Eklo K, Berg T, Sorbye S, Lonvik K, Al-Saad S . Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med. 2011; 9:6. PMC: 3023703. DOI: 10.1186/1479-5876-9-6. View

10.

Kong W, He L, Richards E, Challa S, Xu C, Permuth-Wey J . Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2013; 33(6):679-89. PMC: 3925335. DOI: 10.1038/onc.2012.636. View

11.

Johansson J, Berg T, Kurzejamska E, Pang M, Tabor V, Jansson M . MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene. 2013; 32(50):5614-24. PMC: 3898103. DOI: 10.1038/onc.2013.322. View

12.

Osborne C, Schiff R . Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005; 23(8):1616-22. DOI: 10.1200/JCO.2005.10.036. View

13.

Lai R, Hsiao Y, Wang M, Lin H, Wu C, Chi C . SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett. 2009; 288(1):75-85. DOI: 10.1016/j.canlet.2009.06.025. View

14.

Mattiske S, Suetani R, Neilsen P, Callen D . The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21(8):1236-43. DOI: 10.1158/1055-9965.EPI-12-0173. View

15.

Thai T, Calado D, Casola S, Ansel K, Xiao C, Xue Y . Regulation of the germinal center response by microRNA-155. Science. 2007; 316(5824):604-8. DOI: 10.1126/science.1141229. View

16.

Jiang S, Zhang H, Lu M, He X, Li Y, Gu H . MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010; 70(8):3119-27. DOI: 10.1158/0008-5472.CAN-09-4250. View

17.

Tili E, Michaille J, Adair B, Alder H, Limagne E, Taccioli C . Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis. 2010; 31(9):1561-6. PMC: 4647642. DOI: 10.1093/carcin/bgq143. View

18.

Shou J, Massarweh S, Osborne C, Wakeling A, Ali S, Weiss H . Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96(12):926-35. DOI: 10.1093/jnci/djh166. View

19.

Herynk M, Parra I, Cui Y, Beyer A, Wu M, Hilsenbeck S . Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007; 13(11):3235-43. PMC: 4484622. DOI: 10.1158/1078-0432.CCR-06-2608. View

20.

Hwang M, Min C, Kim H, Lee H, Yoon K, Park S . The nuclear localization of SOCS6 requires the N-terminal region and negatively regulates Stat3 protein levels. Biochem Biophys Res Commun. 2007; 360(2):333-8. DOI: 10.1016/j.bbrc.2007.06.062. View